DMD Celsis microsomes mean better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hashizume, T.
Right arrow Articles by Inaba, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hashizume, T.
Right arrow Articles by Inaba, T.

Vol. 26, Issue 6, 566-571, June 1998

N-Dealkylation and Hydroxylation of Ebastine by Human Liver Cytochrome P450

Takanori Hashizume, Masashi Mise, Yoshiaki Terauchi, Luan O, Toshihiko Fujii, Hisashi Miyazaki, and Tadanobu Inaba

Developmental Research Laboratories, Dainippon Pharmaceutical Co., Ltd. (T.H., M.M., Y.T., T.F., H.M.), and the Department of Pharmacology, University of Toronto (L.O., T.I.)

Ebastine [4'-tert-butyl-4-[4-(diphenylmethoxy)piperidino]butyro phe- none] is a new-generation, nonsedative, H1 antihistamine. The present study was performed to characterize the cytochrome P450 (CYP) isoforms responsible for ebastine N-dealkylation and hydroxylation. Human liver microsomes metabolized ebastine to two major metabolites, i.e. a desbutyrophenone metabolite (des-BP) and hydroxyebastine (M-OH), and the ratio of Vmax values was 3:1. N-Dealkylation yielded des-BP, whereas M-OH, an hydroxylation product, could be further oxidized to the pharmacologically active carebastine. In a panel of 14 human liver microsomal preparations, the rate of dealkylation showed a highly significant correlation with CYP3A-mediated testosterone 6beta -hydroxylation but not with reactions of seven other CYP isoforms. However, there was no correlation between the two pathways for ebastine (dealkylation and hydroxylation). Differential chemical inhibition in liver microsomes, in which dealkylation was more sensitive than hydroxylation, was demonstrated with ketoconazole, troleandomycin, cyclosporin A, and midazolam. Anti-CYP3A antibodies markedly reduced the dealkylation rate (>95%) in liver microsomes but exhibited insignificant effects on hydroxylation (<5%). Among 12 cDNA-expressed human CYP isoforms, which account for up to 70% of the total CYP enzyme content in human liver, CYP3A4 alone metabolized ebastine; the ratio of des-BP to M-OH formation was 12:1. This ratio for metabolism by the pure enzyme was much larger than the ratio (3:1) observed for the microsomal reaction mixture. This change in ratio, which is attributed to a decrease in M-OH formation, indicates that, although ebastine is metabolized to two major metabolites, N-dealkylation to des-BP is mediated by CYP3A, whereas hydroxylation to M-OH appears to be mediated mainly by unidentified enzymes other than CYP3A.


Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
K.-H. Liu, M.-G. Kim, D.-J. Lee, Y.-J. Yoon, M.-J. Kim, J.-H. Shon, C. S. Choi, Y. K. Choi, Z. Desta, and J.-G. Shin
Characterization of Ebastine, Hydroxyebastine, and Carebastine Metabolism by Human Liver Microsomes and Expressed Cytochrome P450 Enzymes: Major Roles for CYP2J2 and CYP3A
Drug Metab. Dispos., November 1, 2006; 34(11): 1793 - 1797.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Matsumoto, T. Hirama, T. Matsubara, K. Nagata, and Y. Yamazoe
Involvement of CYP2J2 on the Intestinal First-Pass Metabolism of Antihistamine Drug, Astemizole
Drug Metab. Dispos., November 1, 2002; 30(11): 1240 - 1245.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Hashizume, S. Imaoka, M. Mise, Y. Terauchi, T. Fujii, H. Miyazaki, T. Kamataki, and Y. Funae
Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 298 - 304.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. Hashizume, M. Mise, S. Matsumoto, Y. Terauchi, T. Fujii, S. Imaoka, Y. Funae, T. Kamataki, and H. Miyazaki
A Novel Cytochrome P450 Enzyme Responsible for the Metabolism of Ebastine in Monkey Small Intestine
Drug Metab. Dispos., June 1, 2001; 29(6): 798 - 805.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.